Nektar (NKTR) Q4 2025 earnings review
Transformative Clinical Data Unlocks Massive Capital Event
Nektar's Q4 financials take a backseat to its recent clinical and corporate milestones. The company reported a net loss of $36.1M on $21.8M in non-cash royalty revenue. However, the real story happened just after the quarter closed: following transformative Phase 2b data for rezpegaldesleukin (REZPEG) in atopic dermatitis and alopecia areata, Nektar raised a staggering $476M in early 2026. This completely removes the prior 'going concern' over Phase 3 funding constraints, granting the company independent optionality to initiate Phase 3 trials in June without being forced into an unfavorable partnership.
🐂 Bull Case
The $432M secondary offering and $44M ATM usage in Feb/March 2026 push pro-forma cash north of $720M. Management no longer needs to aggressively seek a commercial partner to fund the REZPEG Phase 3 program.
The 52-week treatment data for REZPEG showed that complete clearance of disease is possible with monthly or quarterly maintenance dosing, a massive competitive differentiator in the crowded immunology space.
🐻 Bear Case
Moving from the REZOLVE-AD Phase 2b to a global Phase 3 program in June carries operational risk, particularly in controlling the high placebo response rates historically seen in atopic dermatitis trials.
Following the sale of the Huntsville manufacturing facility in late 2024, Nektar relies entirely on non-cash royalties for top-line revenue, meaning all operational burn directly eats into the cash pile.
⚖️ Verdict: 🟢
Bullish. The successful transition from a cash-constrained biotech to a fully funded late-stage entity is complete. The market has validated the REZPEG clinical data with nearly half a billion dollars in fresh capital.
Key Themes
REZPEG Maintenance Data De-Risks Phase 3
In early 2026, Nektar reported 52-week treatment data for REZPEG. The ability to maintain efficacy with monthly and quarterly dosing profiles is a game-changer. This durability validates the underlying Treg-stimulating mechanism and sets up a highly competitive target product profile ahead of the Phase 3 atopic dermatitis initiation in June 2026.
Alopecia Areata Proof-of-Concept Reached
The REZOLVE-AA Phase 2b study successfully established proof-of-concept in the 36-week induction period for patients with severe-to-very-severe alopecia areata. Topline data from the blinded 16-week extension period is due in April 2026, which will be the next major binary catalyst for the stock.
Pipeline Expansion: NKTR-0165 Enters MS
Nektar is officially expanding its pipeline beyond REZPEG. The company established a research collaboration with UCSF to evaluate NKTR-0165, its tumor necrosis factor receptor 2 (TNFR2) agonist antibody, in multiple sclerosis. Preclinical data will be presented in the second half of 2026.
Macro Headwinds: San Francisco Real Estate Drag
Despite clinical momentum, macro real estate factors are bleeding the income statement. The company recorded $8.6M in non-cash restructuring and impairment charges in Q4 ($9.3M for FY25), directly related to the declining San Francisco commercial real estate market and legacy lease obligations.
Gannet BioChem Investment Continues to Drag Earnings
While management celebrates clinical wins, the equity method investment in Gannet BioChem (a remnant of the Huntsville facility sale) remains a persistent financial drag. It generated a $1.3M non-cash loss in Q4, bringing the full-year 2025 non-cash loss to $8.7M, contradicting the otherwise clean operational narrative.
Total Reliance on Non-Cash Royalties
With the divestiture of the Huntsville facility, Nektar's top-line is entirely comprised of non-cash royalty revenue ($21.8M in Q4). While operating expenses have dropped due to zero COGS, the company has no traditional cash-generating product sales to offset its $30M+ quarterly burn rate.
Other KPIs
Stable. Up slightly from $28.7M a year ago, but FY25 total R&D actually decreased to $117.3M (from $120.9M in FY24). This reflects a deliberate capital reallocation: decreasing spend on the oncology asset NKTR-255 to fund the expanding REZPEG dermatological trials.
Decelerating. A sharp drop from $17.1M in Q4 2024. Full-year G&A fell from $76.8M to $68.7M, driven by significant reductions in facilities costs and stock-based compensation. Management is keeping overhead tight ahead of the expensive Phase 3 trials.
Guidance
The company will report topline data from the blinded 16-week treatment extension period for alopecia areata. Management has entered a strict quiet period beginning April 1 until the data is released, underscoring the materiality of this binary event.
The official commencement of the pivotal Phase 3 studies for REZPEG in moderate-to-severe atopic dermatitis. With the $476M cash infusion, the company is fully capitalized to execute this independently.
Key Questions
Partnership Strategy Pivot?
In previous quarters, you stated a partnership would be necessary to fund the REZPEG Phase 3 program. With over $700M in pro-forma cash, does this entirely take a strategic partnership off the table, or does it just change your negotiating leverage?
Phase 3 Placebo Mitigation
You successfully suppressed the placebo response in the REZOLVE-AD Phase 2b trial by limiting U.S. enrollment to 17%. Can you maintain this stringent geographic and site-level control as you scale up into a massive global Phase 3 program?
Gannet BioChem Outlook
The Gannet BioChem equity investment cost the company $8.7M in non-cash losses this year. At what point does this investment stabilize, and is there any strategic path to divesting this remaining stake to clean up the P&L?